lundi 24 août 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source documentNasdaq· April 10, 2026

Novel Drugs Approved By The FDA In 2025

View original at nasdaq.com
Novel Drugs Approved By The FDA In 2025 (RTTNews) - The U.S. Food and Drug Administration (FDA) in 2025 approved 46 novel drugs, including 34 new molecular entities (NMEs) and 12 biologics…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

Data points we hold from this source

U.S. Food and Drug Administration · accelerated approvals11 drugs
U.S. Food and Drug Administration · biologics approved12 biologics
U.S. Food and Drug Administration · fast track designations18 drugs
U.S. Food and Drug Administration · first in class drugs20 drugs
U.S. Food and Drug Administration · new molecular entities approved34 NMEs
U.S. Food and Drug Administration · novel drugs approved46 drugs
U.S. Food and Drug Administration · priority reviews21 drugs
U.S. Food and Drug Administration · rare disease drugs23 drugs
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
Nous signalons les conflits ouvertement ›
Vérifié récemment
Vérifié avec la source d'origine
4,978
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,978 faits vérifiés avec la source5,251 documents sources archivés
Interrogez ces données → isubstrate.com
Novel Drugs Approved By The FDA In 2025 — Source | Via News | fr.VIA.NEWS